Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).

Trial Details

NCT ID

NCT05530421

Phase

PHASE2

Sponsor

University of Miami

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

Selinexor
Venetoclax
Dexamethasone

Locations (sample)

Coral Gables, Florida, United States|25.72149,-80.26838
Deerfield Beach, Florida, United States|26.31841,-80.09977
Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

Patients must have a documented diagnosis of multiple myeloma defined by the International Myeloma Working Group Criteria (IMWG).5 Patients at init…
Anemia: Hemoglobin ≤10 g/dL, or
Renal failure: serum creatinine ≥ 2.0 mg/dL, or
Hypercalcemia: Ca ≥10.5 mg/dL, or

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →